Alkermes plc

“SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD.”

“following the acquisition of Avadel Pharmaceuticals plc in February 2026”

“the first large phase 2 clinical trial to demonstrate positive results with an OX2R agonist in patients with NT2 (n=93).”

“the eight-week randomized, double-blind treatment period”

“optional five-week open-label extension”

“Wednesday, June 17 from 11:00-11:45 a.m.”

“indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.”

“for at least six (6) hours after taking LUMRYZ”

“2% of 107 patients treated with LUMRYZ experienced a confusional state.”

“Anxiety occurred in 7.5% of 107 patients treated with LUMRYZ”

“Sleepwalking, defined as confused behavior occurring at night and at times associated with wandering, was reported in 3% of 107 adult patients with narcolepsy treated with LUMRYZ.”

“case reports of withdrawal, ranging from ... (18 g to 250 g per day) in excess of the recommended dosage range.”

“These symptoms generally abated in three (3) to fourteen (14) days.”

“Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professio…”

“The company will present 26 abstracts”

“LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years …”

“In an adult clinical trial in patients with narcolepsy (n=212), there were no suicide attempts, but one patient with a history of depression and anxiety developed suicidal ideation in the LUMRYZ-trea…”

“In a clinical trial in pediatric narcolepsy patients administered immediate-release sodium oxybate, one patient experienced suicidal ideation and two patients reported depression.”

“During adult clinical trials in patients with narcolepsy administered LUMRYZ, 2% of 107 patients treated with LUMRYZ experienced a confusional state. No patients treated with LUMRYZ discontinued trea…”

“Anxiety occurred in 7.5% of 107 patients treated with LUMRYZ in the adult trial in patients with narcolepsy.”

“Sleepwalking, defined as confused behavior occurring at night and at times associated with wandering, was reported in 3% of 107 adult patients with narcolepsy treated with LUMRYZ. No patients treated…”

“Also caution patients against engaging in these hazardous activities for at least six (6) hours after taking LUMRYZ.”

“Safety and effectiveness of LUMRYZ in pediatric patients below the age of 7 years have not been established.”